Assessment of the efficacy and safety of two albendazole regimens for the treatment of hypermicrofilaraemic loiasis in adults in Woleu-Ntem Province, Gabon: A phase IIb single-blind randomised controlled trial
Daily administration of 400 mg albendazole for 30 days effectively reduces microfilarial loads in patients with L. loa hypermicrofilaraemia and is well tolerated and safe. This pre-treatment regimen may reduce the risk of adverse events associated with ivermectin administration. Further research is needed to evaluate the long-term persistence of microfilarial suppression.
Authors
- Bouyou Akotet M
- Charleine Manomba
- Héléna Noéline Kono
- Reinne Moutongo
- Hadry Roger Sibi Matotou
- Denise Patricia Mawili Mboumba
- Luccheri Ndong Akomezoghe
- Bédrich Pongui Ngondza (ORCID: https://orcid.org/0000-0002-5109-3177)
- Coella Joyce Mihindou
- Valentin Migueba
- L. James
- Christian Mayandza
- Dimitri Ardin Moussavou Mabicka
- Ginette Severine Zang Ondo
- Jacques Mari Ndong Ngomo
- Bridy Chesly Moutombi Ditombi
- Noé Patrick M’Bondoukwé
Institutions
- Université des Sciences de la Santé (GA)
Publication Details
- Journal
- PLoS neglected tropical diseases
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1371/journal.pntd.0013166
- Primary Topic
- Parasitic Diseases Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European and Developing Countries Clinical Trials Partnership